A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)
      QxMD      Google Scholar   
Citation:
Oncologist vol 24 (5) 589-e160
Year:
2019
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
8
Parents:
578  
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U10CA180790, UG1CA189863  
Corr. Author:
 
Authors:
                   
Networks:
LAPS-MN026, METROMIN   
Study
NCCTG-N064B
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
4, 6, 31, Clinical Trial Results